We don't charge dispensing fee
Shipped and delivered directly to your doorstep
Brilinta (active ingredient: ticagrelor) is a prescription medication indicated for the following:
Brilinta belongs to a class of drugs known as platelet aggregation inhibitors or antiplatelet agents, specifically P2Y12 platelet inhibitors, which work by inhibiting platelet activation and aggregation, thereby reducing the risk of blood clot formation and subsequent cardiovascular events.
BRILINTA (ticagrelor) is a tablet to be taken orally. For patients who are unable to swallow tablets whole, BRILINTA tablets can be crushed, mixed with water, and drunk. The mixture can also be administered via a nasogastric tube (CH8 or greater). It is important to flush the nasogastric tube through with water after administration of the mixture. Additionally, the dose should be adjusted in patients with renal impairment.
In the management of Acute Coronary Syndrome (ACS), Brilinta (ticagrelor) should be initiated with a 180 mg loading dose. This should be followed by 90 mg twice daily during the first year after an ACS event. After one year, the dosage should be reduced to 60 mg twice daily for maintenance.
For prevention of first heart attack or stroke in patients with coronary artery disease (CAD), adults should take 60 milligrams (mg) of BRILINTA two times a day. Your doctor may also give you a maintenance dose of 75 to 100 mg aspirin once a day to be taken together with this medicine.
Brilinta and its generic alternative Ticagrelor are available in the following forms and strengths:
The use of ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial hemorrhage, and in patients with severe hepatic impairment.
You will usually be prescribed aspirin with Brilinta to reduce the chance of a blood clot forming. Using Brilinta and aspirin together is called “dual antiplatelet therapy”. Do not stop either of these medications without speaking to your doctor first, as that can increase your risk of a heart attack, stroke, or death.
Brilinta is meant to be used as a long-term treatment. Current treatment guidelines recommend that most people who take Brilinta should be on the drug for at least 6 to 12 months.
Most patients are prescribed one 90 mg dose of Brilinta twice daily for 12 months. The medication should be taken around the same time each day (i.e., one tablet in the morning and one in the evening).
Generic name: | Ticagrelor |
---|---|
Formulation: | Blister Tablets, Tablet |
Strength(s): | 60mg, 90mg |
Quantities Available: | 56, 60, 84, 100, 112, 168, 200 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Brilinta (ticagrelor) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is standard for prescription medications to ensure continuous treatment without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Brilinta is commonly prescribed in dosages of 90 mg and 60 mg, taken twice daily. For a 90-day supply, you would order 180 tablets (90 days x 2 tablets per day).
Yes, we do sell ticagrelor on our website. You can enjoy low prices for this medication. However, please note that you will need a valid prescription from your healthcare provider in order to purchase ticagrelor from us. We require this prescription to dispense the medication safely and legally. You can conveniently provide your prescription by mailing, faxing, or uploading it through your online account on our website.
Yes, we ship Brilinta (ticagrelor) to both the United States and Puerto Rico.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Brilinta (Ticagrelor). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Brilinta (Ticagrelor).
REVIEWS